News

Demand for outsourced services to provide clinical development capacity and expertise has grown substantially over the last 10 years.

Promising new approaches to optimize data and outcomes.

Few topics occasion the lamentations of clinical trial professionals more than the topic of patient inclusion/exclusion criteria in clinical protocols.

The identification of concomitant medication poses specific challenges in oncology data reporting.

Chiltern, a global CRO headquartered in the UK, announced it has signed a purchase agreement to acquire Theorem Clinical Research, based in Wilmington, NC. The combined company will operate under the name Chiltern and will gain global reach - most notably in China and Japan - as well as new service offerings for medical devices and diagnostics, clinical analytics and clinical supplies. The transaction is expected to close within the next several weeks. 

With more than 60 percent of cancers in the United States occurring in people age 65 and older, the evidence base for treating older adults is sparse.

Epic Sciences announced an agreement with LabCorp to provide circulating tumor cell (CTC) technology and support oncology clinical trials in Asia through Covance Drug Development.

Cedars-Sinai announced that its Research for Her online registry that matches women with research studies and clinical trials.

While still early days, key metrics can be collected in three broad areas

The number of site audits performed has grown significantly.

The four essential steps to ensuring optimal clinical deliverable specifications and process controls.

Whether we are referring to CSRs or to IPD, the personal information of trial participants needs to be de-identified prior to release. This article will describe the available methods for de-identifying clinical trial data, and the relative strengths and weaknesses of each.